BloodHumansLeukemiaMyeloidAcuteCCAAT-Enhancer-Binding Proteins
MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.
Dorien Pastoors, Marije Havermans, Roger Mulet-Lazaro, Leonie Smeenk, Sophie Ottema, Claudia Erpelinck-Verschueren, Stanley van Herk, Maikel Anthonissen, Tim Grob, Shruthi Subramanian, Julie A I Thoms, John E Pimanda, Bas J Wouters, Berna Beverloo, Torsten Haferlach
Published: 202510.1182/blood.2025028914
Abstract
ABSTRACT: The transcription factor MECOM, located at 3q26, is essential for hematopoietic stem cells in healthy individuals. Enhancer translocations, due to 3q26 rearrangements, drive out-of-context MECOM expression in one of the most aggressive subt…
Preview only. Read the full abstract at the source